Skip to main content

Table 1 Basal characteristics of Isfahani adult people (n = 615) with newly thyroid function in 2011 were euthyroid in 2006

From: Incidence of thyroid dysfunction in an Iranian adult population: the predictor role of thyroid autoantibodies: results from a prospective population-based cohort study

 

Euthyroid, n (%)

Subclinical hypothyroidism, n (%)

OR (CI 95%)

Overt hypothyroidism, n (%)

OR (CI 95%)

Overt + subclinical hypothyroidism, n (%)

OR (CI 95%)

Subclinical hyperthyroidism, n (%)

OR (CI 95%)

Overt hyperthyroidism, n (%)

OR (CI 95%)

Overt + subclinical hyperthyroidism, n (%)

OR (CI 95%)

Sex

 Men

281 (54.1)

27 (37.5)

1.96 (1.18–3.26)*

4 (44.4)

1.47 (0.39–5.55)

31 (38.3)

1.90 (1.17–3.07)*

2 (20)

4.7 (0.99–22.45)*

0 (0)

 

2 (13.3)

7.67 (1.17–34.34)*

 Women

238 (45.9)

45 (62.5)

5 (55.6)

50 (61.7)

8 (80)

5 (100)

13 (86.6)

Age (years)

 20–40

153 (29.7)

14 (19.4)

1

4 (44.4)

1

18 (22.2)

1

4 (40)

1

2 (40)

1

6 (40)

1

 40–60

274 (53.2)

42 (58.3)

1.67 (0.88–3.16)

2 (22.2)

0.27 (0.05–1.54)

44 (54.3)

1.36 (0.76–2.44)

5 (50)

0.69 (0.18–2.63)

2 (40)

0.55 (0.07–4.00)

7 (46.7)

0.65 (0.21–1.97)

 ≥60

88 (17.1)

16 (22.2)

1.98 (0.92–4.26)

3 (33.3)

1.3 (0.28–5.96)

19 (23.5)

1.83 (0.91–3.68)

1 (10)

0.43 (0.04–3.95)

1 (20)

0.86 (0.07–9.7)

2 (13.3)

0.58 (0.11–2.93)

BMI (kg/m2)

 <25

151 (29.9)

22 (31.4)

1

2 (22.2)

1

24 (30.4)

1

0 (0)

1

3 (60)

1

3 (20)

1

 25–30

230 (45.5)

27 (38.6)

0.8 (0.44–1.46)

3 (33.3)

0.98 (0.16–5.96)

30 (38.0)

0.82 (0.46–1.45)

5 (50)

 

1 (20)

0.21 (0.02–2.12)

6 (40)

1.31 (0.32–5.33)

 ≥30

124 (24.6)

21 (30)

1.1 (0.61–2.21)

4 (44.4)

2.43 (0.43–16.51)

25 (31.6)

1.26 (0.69–2.33)

5 (50)

 

1 (20)

0.40 (0.04–3.95)

6 (40)

2.43 (0.59–9.93)

FPG (mg/d)

 <100

289 (56.2)

51 (70.8)

1

7 (77.8)

1

58 (71.6)

1

7 (77.8)

1

2 (40)

1

9 (64.3)

1

 100–126

176 (34.2)

17 (23.6)

0.54 (0.3–0.97)*

1 (11.1)

0.23 (0.02–1.92)

18 (22.2)

0.51 (0.29–0.89)*

2 (22.2)

0.46 (0.09–2.28)

1 (20)

0.82 (0.07–9.12)

3 (21.4)

0.54 (0. 14–2.04)

 ≥126

49 (9.5)

4 (5.6)

0.46 (0.16–1.33)

1 (11.1)

0.84 (0.10–6.99)

5 (6.2)

0.5 (0.19–1.33)

0 (0)

 

2 (40)

5.8 (0.81–42.85)

2 (14.3)

1.31 (0.27–6.24)

Smoking

 Yes

42 (8.1)

4 (5.6)

0.66 (0.23–1.92)

1 (11.1)

1.42 (0.17–11.62)

5 (6.1)

0.74 (0.28–1.94)

1 (10)

1.26 (0.15–10.2)

0 (0)

 

1 (6.7)

0.81 (0.1–6.32)

 No

477 (91.9)

68 (94.4)

8 (88.9)

76 (93.9)

9 (90)

5 (100)

14 (93.3)

Positive family history

 Yes

132 (26.4)

29 (40.8)

1.92 (1.15–3.21)*

2 (22.2)

0.79 (0.16–3.88)

31 (38.8)

1.76 (1.07–2.88)*

7 (77.8)

9.75 (2.0–47.65)*

2 (40)

1.85 (0.30–11.24)

9 (64.3)

5 (1.65–15.24)*

 No

368 (73.6)

42 (59.2)

7 (77.8)

49 (61.3)

2 (22.2)

3 (60)

5 (35.7)

TPOAb (IU/mL)

 Positive

110 (23.4)

27 (42.2)

2.39 (1.39–4.11)*

4 (50)

3.2 (0.8–13.33)

31 (43.1)

2.48 (1.46–4.14)*

8 (80)

13.12 (2.74–62.72)*

4 (80)

13.12 (1.45–118.6)*

12 (80)

13.12 (3.63–47.35)*

TgAb (IU/mL)

 Positive

3 (9.4)

2 (25)

3.22 (0.43–23.65)

1 (100)

0

3 (33.3)

4.83 (0.77–30)

0 (0)

 

0 (0)

 

0 (0)

 
  1. BMI body mass index, FPG fasting plasma glucose, TPOAb Thyroid peroxidase antibody, as considered positive when level >75 IU/mL, TgAb thyroid globulin antibody as considered positive when level >100 IU/mL, CI confidence interval
  2. P value <0.05